- Home
- CPF vs ABUS Comparison
CPF vs ABUS Comparison
Compare CPF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPF
- ABUS
- Stock Information
- Founded
- CPF 1954
- ABUS N/A
- Country
- CPF United States
- ABUS United States
- Employees
- CPF N/A
- ABUS N/A
- Industry
- CPF Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- CPF Finance
- ABUS Health Care
- Exchange
- CPF Nasdaq
- ABUS Nasdaq
- Market Cap
- CPF 717.2M
- ABUS 629.1M
- IPO Year
- CPF N/A
- ABUS N/A
- Fundamental
- Price
- CPF $28.36
- ABUS $3.42
- Analyst Decision
- CPF Buy
- ABUS Strong Buy
- Analyst Count
- CPF 1
- ABUS 4
- Target Price
- CPF $30.00
- ABUS $5.50
- AVG Volume (30 Days)
- CPF 198.6K
- ABUS 646.4K
- Earning Date
- CPF 01-29-2025
- ABUS 03-03-2025
- Dividend Yield
- CPF 3.80%
- ABUS N/A
- EPS Growth
- CPF N/A
- ABUS N/A
- EPS
- CPF 1.97
- ABUS N/A
- Revenue
- CPF $240,630,000.00
- ABUS $6,742,000.00
- Revenue This Year
- CPF N/A
- ABUS N/A
- Revenue Next Year
- CPF $6.49
- ABUS N/A
- P/E Ratio
- CPF $14.42
- ABUS N/A
- Revenue Growth
- CPF N/A
- ABUS N/A
- 52 Week Low
- CPF $18.19
- ABUS $2.30
- 52 Week High
- CPF $33.25
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- CPF 42.44
- ABUS 54.07
- Support Level
- CPF $29.27
- ABUS $3.24
- Resistance Level
- CPF $29.95
- ABUS $3.44
- Average True Range (ATR)
- CPF 0.75
- ABUS 0.12
- MACD
- CPF -0.13
- ABUS 0.01
- Stochastic Oscillator
- CPF 3.45
- ABUS 55.56
About CPF Central Pacific Financial Corp New
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.